Get started
Author

Heather Dainton-Smith

Observed institution: Autolus (United Kingdom)
ORCID: 0009-0001-8932-5789
Observed ORCID: 0009-0001-8932-5789
OpenAlex ID: A5140960798
TRBC1-CAR T cell therapy in peripheral T cell lymphoma: a phase 1/2 trial
2024 · Kate Cwynarski, Gloria Iacoboni, et al. · Nature Medicine · 52
CD19 CAR T-Cell Therapy for Treatment of Chronic Graft-versus-Host Disease
2026 · Karamjeet S. Sandhu, Jessica Cheng, et al. · New England Journal of Medicine · 2
CAR T-cell Kinetics, Persistence, and Clinical Outcomes in Adult Patients with Relapsed/Refractory B-cell ALL Treated with Obecabtagene Autoleucel in the FELIX Study
2026 · Claire Roddie, William Day, et al. · Cancer Research Communications · 1
Figure 2 from CAR T-cell Kinetics, Persistence, and Clinical Outcomes in Adult Patients with Relapsed/Refractory B-cell ALL Treated with Obecabtagene Autoleucel in the FELIX Study
2026 · Claire Roddie, William Day, et al.
Supplementary Table S1 from CAR T-cell Kinetics, Persistence, and Clinical Outcomes in Adult Patients with Relapsed/Refractory B-cell ALL Treated with Obecabtagene Autoleucel in the FELIX Study
2026 · Claire Roddie, William Day, et al.
Supplementary Table S3 from CAR T-cell Kinetics, Persistence, and Clinical Outcomes in Adult Patients with Relapsed/Refractory B-cell ALL Treated with Obecabtagene Autoleucel in the FELIX Study
2026 · Claire Roddie, William Day, et al.
Figure 5 from CAR T-cell Kinetics, Persistence, and Clinical Outcomes in Adult Patients with Relapsed/Refractory B-cell ALL Treated with Obecabtagene Autoleucel in the FELIX Study
2026 · Claire Roddie, William Day, et al.
Supplementary Table S5 from CAR T-cell Kinetics, Persistence, and Clinical Outcomes in Adult Patients with Relapsed/Refractory B-cell ALL Treated with Obecabtagene Autoleucel in the FELIX Study
2026 · Claire Roddie, William Day, et al.
Data from CAR T-cell Kinetics, Persistence, and Clinical Outcomes in Adult Patients with Relapsed/Refractory B-cell ALL Treated with Obecabtagene Autoleucel in the FELIX Study
2026 · Claire Roddie, William Day, et al.
Supplementary Figure S1 from CAR T-cell Kinetics, Persistence, and Clinical Outcomes in Adult Patients with Relapsed/Refractory B-cell ALL Treated with Obecabtagene Autoleucel in the FELIX Study
2026 · Claire Roddie, William Day, et al.
Figure 3 from CAR T-cell Kinetics, Persistence, and Clinical Outcomes in Adult Patients with Relapsed/Refractory B-cell ALL Treated with Obecabtagene Autoleucel in the FELIX Study
2026 · Claire Roddie, William Day, et al.
Supplementary Table S6 from CAR T-cell Kinetics, Persistence, and Clinical Outcomes in Adult Patients with Relapsed/Refractory B-cell ALL Treated with Obecabtagene Autoleucel in the FELIX Study
2026 · Claire Roddie, William Day, et al.
Supplementary Table S2 from CAR T-cell Kinetics, Persistence, and Clinical Outcomes in Adult Patients with Relapsed/Refractory B-cell ALL Treated with Obecabtagene Autoleucel in the FELIX Study
2026 · Claire Roddie, William Day, et al.
Figure 4 from CAR T-cell Kinetics, Persistence, and Clinical Outcomes in Adult Patients with Relapsed/Refractory B-cell ALL Treated with Obecabtagene Autoleucel in the FELIX Study
2026 · Claire Roddie, William Day, et al.
Supplementary Table S4 from CAR T-cell Kinetics, Persistence, and Clinical Outcomes in Adult Patients with Relapsed/Refractory B-cell ALL Treated with Obecabtagene Autoleucel in the FELIX Study
2026 · Claire Roddie, William Day, et al.
Table 1 from CAR T-cell Kinetics, Persistence, and Clinical Outcomes in Adult Patients with Relapsed/Refractory B-cell ALL Treated with Obecabtagene Autoleucel in the FELIX Study
2026 · Claire Roddie, William Day, et al.
Figure 1 from CAR T-cell Kinetics, Persistence, and Clinical Outcomes in Adult Patients with Relapsed/Refractory B-cell ALL Treated with Obecabtagene Autoleucel in the FELIX Study
2026 · Claire Roddie, William Day, et al.
Works count: 17
Citation count: 55
H-index: 2
I10-index: 1
Year
Topic
Type